Source comparison
Tesamorelin for Body Composition: Peptide Comparison
Before selecting tesamorelin for body composition research, understanding how it compares mechanistically and clinically to related peptides clarifies which tool fits which experimental objective. Tesamorelin GHRH receptor agonist; stimulates endogenous GH sec
This comparison does not assign a generated winner or score.
- Before selecting tesamorelin for body composition research, understanding how it compares mechanistically and clinically to related peptides clarifies which tool fits which experimental objective.
- Tesamorelin
- GHRH receptor agonist; stimulates endogenous GH secretion
- Selective visceral adipose tissue reduction
- 15–18% over 26 weeks
- Pulsatile (mimics natural secretion)
- Gold standard for VAT-specific reduction with minimal SAT impact; requires daily dosing; effect reverses upon cessation
- Sermorelin
- GHRH analogue; shorter half-life than tesamorelin
- Modest total body fat reduction; some VAT effect
- 8–12% (less selective)
- Pulsatile
- Shorter half-life (10–20 min) limits consistent receptor engagement; better for GH deficiency contexts than targeted VAT reduction
- Ipamorelin
- Ghrelin receptor agonist (growth hormone secretagogue)
- Lean mass preservation; mild fat oxidation
- 5–8% (non-selective)
- Gentler GH stimulation with lower insulin resistance risk; combines well with GHRH analogues in stacked protocols for synergistic effect
- CJC-1295 (with DAC)
- GHRH analogue with drug affinity complex; extended half-life (6–8 days)
- Total body fat reduction; lean mass gain
- 10–14% (less VAT-selective)
- Sustained (non-pulsatile due to long half-life)
- Sustained GH elevation risks receptor downregulation and glucose intolerance; less suitable for VAT-specific research
- Exogenous GH (recombinant human growth hormone)
- Direct GH receptor agonism
- Total fat reduction; significant lean mass gain
- 15–20% (non-selective)
- Sustained (supraphysiological levels)
- Highest potency but greatest metabolic side-effect burden (insulin resistance, edema, joint pain); legal restrictions limit research access
- Tesamorelin's VAT selectivity and pulsatile GH release pattern make it uniquely suited for research applications targeting visceral fat reduction without the anabolic or metabolic complications of sustained GH exposure. For labs exploring combined growth hormone and ghrelin receptor pathways, our Tesamorelin Ipamorelin Growth Hormone Stack provides precise dosing of both peptides in a single reconstituted solution.